folder Filed in Funding daily
IASO Biotherapeutics closes $108 million Series C financing
By Tsani Gramatikova access_time 1 min read

What is IASO Biotherapeutics?

IASO Biotherapeutics is a biopharmaceutical company.

What does IASO Biotherapeutics do?

The company engages in the discovery, development, and commercialization of cell therapies in oncology.

Who owns IASO Biotherapeutics?

Wen (Maxwell) Wang, M.D., Ph. D. founded the company in 2017 in Nanjing, China.

How much has IASO Biotherapeutics raised?

IASO Biotherapeutics announced the completion of Series C financing of $108 million. The startup has raised a total of $168 million in funding over two rounds.

Who has invested in IASO Biotherapeutics?

Eight investors fund IASO Biotherapeutics. Co-Stone Venture Capital and Everbright are the most recent investors.

What domain name does IASO Biotherapeutics operate on?

The company has chosen the domain name.

Related reads

Health tech startup HexaHealthpicks up $1.5 million in Seed funding

Digital Health Startups 2021

The power of purpose: Getting to the heart of branding during the coronavirus crisis

What could happen if you become big and don’t have the .com for your name

Biotherapeutics branding business domain name health IASO oncology therapies